Aquestive Therapeutics Inc. (NASDAQ:AQST) shares traded -5.48% lower at $0.89 on Wall Street last session.
In accordance with the data, 7 analysts cover Aquestive Therapeutics Inc. (NASDAQ:AQST). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.50 and a low of $2.00, we find $5.00. Given the previous closing price of $0.94, this indicates a potential upside of 431.91 percent. AQST stock price is now -4.03% away from the 50-day moving average and -18.67% away from the 200-day moving average. The market capitalization of the company currently stands at $48.72M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 7. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
, while ‘Lake Street’ rates the stock as ‘Buy’.
In other news, Boyd Peter E., SVP-Bus. Process & Info. Tech. bought 5,000 shares of the company’s stock on Jun 14. The stock was bought for $4,050 at an average price of $0.81. Upon completion of the transaction, the SVP-Bus. Process & Info. Tech. now directly owns 59,532 shares in the company, valued at $52983.48. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 08, General Counsel BRAENDER LORI J bought 13,761 shares of the business’s stock. A total of $13,211 was incurred on buying the stock at an average price of $0.96. This leaves the insider owning 38,761 shares of the company worth $34497.29. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AQST stock. A new stake in Aquestive Therapeutics Inc. shares was purchased by HIGHTOWER ADVISORS, LLC during the first quarter worth $116,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP invested $21,000 in shares of AQST during the first quarter. In the first quarter, ROYAL BANK OF CANADA acquired a new stake in Aquestive Therapeutics Inc. valued at approximately $18,000. GSA CAPITAL PARTNERS LLP acquired a new stake in AQST for approximately $12,000. BAYESIAN CAPITAL MANAGEMENT, LP purchased a new stake in AQST valued at around $9,000 in the second quarter. In total, there are 65 active investors with 29.60% ownership of the company’s stock.
Aquestive Therapeutics Inc. (NASDAQ: AQST) opened at $0.9450 on Tuesday. During the past 12 months, Aquestive Therapeutics Inc. has had a low of $0.62 and a high of $3.19. The fifty day moving average price for AQST is $0.9307 and a two-hundred day moving average price translates $1.0983 for the stock.
The latest earnings results from Aquestive Therapeutics Inc. (NASDAQ: AQST) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.36, inline with analysts’ expectations of -$0.36. This compares to -$0.37 EPS in the same period last year. The company reported revenue of $11.46 million for the quarter, compared to $13.29 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -13.73 percent. For the current quarter, analysts expect AQST to generate $11.04M in revenue.
Aquestive Therapeutics Inc.(AQST) Company Profile
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company’s proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
